Gsa Capital Partners LLP Mei Pharma, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.42 - $0.65 $25,587 - $39,599	-60,923 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$0.54 - $2.74 $17,307 - $87,817	32,050 Added 111.0%	60,923 $37,000
Q4 2021 Feb 14, 2022	SELL	$2.33 - $3.37 $61,097 - $88,368	-26,222 Reduced 47.59%	28,873 $77,000
Q3 2021 Nov 12, 2021	BUY	$2.52 - $2.99 $69,055 - $81,934	27,403 Added 98.96%	55,095 $152,000
Q2 2021 Aug 05, 2021	BUY	$2.6 - $3.65 $71,999 - $101,075	27,692 New	27,692 $79,000
Q1 2021 May 10, 2021	SELL	$2.73 - $4.5 $242,937 - $400,446	-88,988 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$2.6 - $3.32 $231,368 - $295,440	88,988 New	88,988 $235,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $397M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.